Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4

BACKGROUND: Checkpoint inhibitors (CPIs) such as anti-PD(L)-1 and anti-CTLA-4 antibodies have resulted in unprecedented rates of antitumor responses and extension of survival of patients with a variety of cancers. But some patients fail to respond or initially respond but later relapse as they devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Lisa A, Marubayashi, Sachie, Jorapur, Aparna, Jacobson, Scott, Zibinsky, Mikhail, Robles, Omar, Hu, Dennis Xiaozhou, Jackson, Jeffrey J, Pookot, Deepa, Sanchez, Jerick, Brovarney, Martin, Wadsworth, Angela, Chian, David, Wustrow, David, Kassner, Paul D, Cutler, Gene, Wong, Brian, Brockstedt, Dirk G, Talay, Oezcan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692993/
https://www.ncbi.nlm.nih.gov/pubmed/33243932
http://dx.doi.org/10.1136/jitc-2020-000764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692993/
https://www.ncbi.nlm.nih.gov/pubmed/33243932
http://dx.doi.org/10.1136/jitc-2020-000764

Ejemplares similares